| Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that its current joint venture target, Amarantus BioSciences, Inc., has achieved positive results in a pre-clinical experiment demonstrating the potential of its new Parkinson's disease therapy currently in development. Amarantus is the developer of MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis. The experime...continued RBCC |
Wednesday, May 2, 2012
RBCC Target Amarantus BioSciences Reports Positive Pre-Clinical Results of Parkinson's Treatment
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment